The University of Chicago Header Logo


Peter Riedell to Lymphoma, Non-Hodgkin

This is a "connection" page, showing publications Peter Riedell has written about Lymphoma, Non-Hodgkin.
Connection Strength

  1. Advances in CAR T-Cell Therapy for Aggressive B-NHL. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S94-S97.
    View in: PubMed
    Score: 0.665
  2. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023 09 26; 7(18):5579-5585.
    View in: PubMed
    Score: 0.205
  3. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2023 07 11; 7(13):3192-3198.
    View in: PubMed
    Score: 0.203
  4. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2023 07; 29(7):449.e1-449.e7.
    View in: PubMed
    Score: 0.200
  5. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol. 2021 Jul 01; 7(7):993-1003.
    View in: PubMed
    Score: 0.176
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.